MRNA
No price yet
Announcements
Nothing here yet
Daily updates
- Moderna announced that late-breaking Phase 3 INTerpath-001 results for intismeran autogene plus pembrolizumab in resected stage IIB-IV melanoma will be presented at an ESMO Presidential Symposium on October 24.Sep 22, 2026
- INTerpath-001 Phase 3 trial met RFS and DMFS endpoints in melanomaAug 20, 2026
- INTerpath-001 Phase 3 trial met RFS and DMFS endpoints in melanomaAug 19, 2026
- FDA approves Moderna's mFLUSIVA influenza vaccine for adults 50 and olderAug 6, 2026
FDA designations
Nothing here yet
News
- Moderna received FDA approval for its updated 2026-2027 COVID-19 vaccinesAug 28, 2026
- Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free and distant metastasis-free survival endpoints in completely resected stage IIB-IV melanomaAug 19, 2026
- Moderna initiated a Phase 1 clinical trial of its investigational mRNA-1469 vaccine against Bundibugyo ebolavirusAug 6, 2026
- Moderna received U.S. FDA approval for its mFLUSIVA influenza vaccineAug 6, 2026
- Moderna dosed the first participant in a Phase 1 trial of its investigational tumor-targeted cancer antigen therapyJul 16, 2026